Psychedelic Medicine

A new study has gone to extraordinary lengths to investigate how strong the placebo effect may be in psychedelic research. The experiment staged a fake party to explore exactly how much of a psychedelic experience can be generated with a placebo.

A study tracking the potency of cannabis products found most medical marijuana is stronger than it needs to be for pain relief. The research suggests high THC levels are unnecessary for medical uses and can increase the risk of negative side effects.

A new report describes three cases of accidental LSD overdoses leading to strangely positive outcomes, including the story of a woman who inadvertently took 500 times a normal dose. New Atlas spoke to Mark Haden, one of the report's authors, to learn more.

A team of researchers from King’s College London has, for the first time, imaged the brains of patients with psychosis under the influence of CBD. The study demonstrates the anti-psychotic potential of CBD, suggesting clinical trials are necessary.

A new study is offering the first long-term insights into the efficacy of a single dose of psilocybin, in conjunction with psychotherapy, in treating depression and anxiety in patients with life-threatening cancer.

Marking an impressive milestone in the development of MDMA-assisted psychotherapy for PTSD, the FDA has approved the treatment for Expanded Access, allowing certain patients access to the therapy before full market approval is granted.

A new study has described the discovery of a previously unknown cannabinoid. Dubbed THCP, the molecule is significantly more potent that its well-known counterpart THC, however, it is unknown how present it is in common cannabis strains.

New Atlas spoke to several leading psychedelic researchers to get their thoughts on three big future-forward questions. Where will psychedelic science be in 2030, what hurdles do researchers face, and what research topic is yet to be answered?

Results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing LSD. This Phase 1 trial is exploring whether microdosing could be useful as a therapeutic tool to treat Alzheimer’s disease.

Researchers are reporting positive results from an early trial exploring the safety profile of psilocybin doses in healthy adults. The trial also explored the potential of group dosing sessions as a way to speed up research and expand patient access.

Predicting a wave of psychedelic legalization over the coming decade, start-up Silo Wellness has developed a magic mushroom nasal spray focused on delivering controlled psychedelic microdoses. New Atlas spoke to CEO Mike Arnold to learn more.

An incredible new study has found a specifically timed infusion of ketamine can rewrite maladaptive reward memories. Subjects with harmful alcohol behaviors significantly reduced their drinking for nine months following a single ketamine treatment.